Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?

IBTV speaks with industry leaders at ASGCT 2026 about new approaches to manufacturing, reimbursement, treatment delivery, and long-term value that could bring cell and gene therapies to more patients

September 11, 2026
2 min

The Medicine Maker

Objective:

To explore how the cell and gene therapy sector can rethink value, access, and affordability as therapies transition from clinical trials to routine care.

Approach:

Discussion: Industry leaders share insights on the challenges and potential solutions regarding access to cell and gene therapies.

Key Findings:

High manufacturing costs and complex delivery pathways restrict patient access to cell and gene therapies.
Uncertain reimbursement models pose additional barriers to access.
Reducing production costs and treating patients earlier could enhance accessibility.
Expanding delivery beyond specialist centers is necessary for broader access.
Long-term value assessment of therapies is crucial, rather than focusing solely on upfront costs.

Interpretation:

Collaboration among manufacturers, regulators, healthcare systems, payers, and patient advocates is essential for improving access to cell and gene therapies.

Limitations:

The discussion does not provide specific strategies or frameworks for implementation.
Insights are based on perspectives from industry leaders without empirical data.

Conclusion:

Addressing the challenges of value, access, and affordability in cell and gene therapy requires a multifaceted approach involving various stakeholders.